Carmine J. Durham
Oprichter bij Zurex Pharma, Inc.
Profiel
Carmine J.
Durham is the founder of Zurex Pharma, Inc. Prior to founding Zurex Pharma, he worked as a Principal at Merck & Co., Inc. and held marketing and director positions at Abbott Laboratories, BASF Pharma Ltd., Knoll Pharmaceutical Co., and Boehringer Mannheim Pharmaceuticals Corp.
He also served as Vice President of Corporate Development & Strategy at Bone Care International, Inc. and Vice President of Corporate Development & Commercial Strategy at Ash Access Technology, Inc. Mr. Durham earned his undergraduate degree from The University of New Mexico in 1988.
Actieve functies van Carmine J. Durham
| Bedrijven | Functie | Begin |
|---|---|---|
Zurex Pharma, Inc.
 Zurex Pharma, Inc. Medical SpecialtiesHealth Technology Zurex Pharma, Inc. provides safe and effective anti-microbial products. Its products include ZuraPrep, a pre-surgical skin preparation for the prevention of SSI; ZurAsept, an antimicrobial and antithrombotic catheter solution to reduce CRBSI; and ZuraGard that prevents extra-luminal or exit site wound CRBSI. The company was founded in April 2008 and is headquartered in Middleton, WI. | Oprichter | - |
Eerdere bekende functies van Carmine J. Durham
| Bedrijven | Functie | Einde |
|---|---|---|
| Knoll Pharmaceutical Co. | Verkoop & Marketing | - |
| MERCK & CO., INC. | Corporate Officer/Principal | - |
BASF Pharma Ltd.
 BASF Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million. | Verkoop & Marketing | - |
| Boehringer Mannheim Pharmaceuticals Corp. | Verkoop & Marketing | - |
| ABBOTT LABORATORIES | Corporate Officer/Principal | - |
Opleiding van Carmine J. Durham
| The University of New Mexico | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| MERCK & CO., INC. | Health Technology |
| Bedrijven in privébezit | 6 |
|---|---|
Bone Care International, Inc.
 Bone Care International, Inc. Pharmaceuticals: OtherHealth Technology Bone Care International, Inc. developed innovative therapeutic products. Its products included Hectorol Injections and Capsules. The company was located in Middleton, WI. | Health Technology |
Ash Access Technology, Inc.
 Ash Access Technology, Inc. Medical SpecialtiesHealth Technology Ash Access Technology, Inc. develops catheters, antimicrobials, vascular access devices and other catheter-related products and services. Its products include zuragen Injection, zuraprep, centros and pipeline. The firm engages in the development and commercialization of proprietary technologies and devices to treat and prevent the clinical consequences of diseases and disorders related to vascular access. The company was founded by Robert B. Truitt and Stephen R. Ash in 1983 and is headquartered in Lafayette, IN. | Health Technology |
| Boehringer Mannheim Pharmaceuticals Corp. | |
BASF Pharma Ltd.
BASF Pharma Ltd. Pharmaceuticals: MajorHealth Technology Part of Abbott Laboratories, BASF Pharma Ltd. is a British company that produces excipients and active ingredients. The company is based in Kent, UK. The company was founded by Erich Schlick. BASF Pharma was acquired by Abbott Laboratories from BASF SE on March 02, 2001 for $6,128.79 million. | Health Technology |
Zurex Pharma, Inc.
Zurex Pharma, Inc. Medical SpecialtiesHealth Technology Zurex Pharma, Inc. provides safe and effective anti-microbial products. Its products include ZuraPrep, a pre-surgical skin preparation for the prevention of SSI; ZurAsept, an antimicrobial and antithrombotic catheter solution to reduce CRBSI; and ZuraGard that prevents extra-luminal or exit site wound CRBSI. The company was founded in April 2008 and is headquartered in Middleton, WI. | Health Technology |
| Knoll Pharmaceutical Co. |
